Sugi Predict

Sugi Predict / Compounds / SCHEMBL1157767

SCHEMBL1157767

SCHEMBL1157767

COc1ccc(N(Cc2cccnc2)c2ccc(-c3nn[nH]n3)cc2)cc1OC1CCCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 6/20 0.40
▸ PDE4B Q07343 5/20 0.40
▸ PDE4C Q08493 4/20 0.40
▸ PDE4D Q08499 4/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ FGFR2 P21802 1/20 0.39
▸ FGFR4 P22455 1/20 0.39
▸ FGFR3 P22607 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ XDH P47989 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ CYP2A6 P11509 1/20 0.36
▸ PTAFR P25105 2/20 0.36
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ CXCR3 P49682 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157932 0.90 PDE4B (0.36) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4206163 0.89 PDE4A (0.38) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157355 0.89 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1156850 0.86 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL6070487 0.85 TAS2R14 (0.40) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157495 0.85 PDE4A (0.47) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL4195871 0.84 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157804 0.84 FGFR3 (0.42) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL1157468 0.84 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL2931327 0.84 PDE4B (0.41) PDE4APDE4BALDH1A1XDHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 — — US claimed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 — — EP claimed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 — — US claimed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 — — US claimed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 — — WO claimed
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 — — US disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 — — US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 — — US disclosed
US-7205320-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2007-04-17 — — US disclosed
US-20070078139-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2007-04-05 — — US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 — — US disclosed
US-20040230072-A1 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A (US) 2004-11-18 — — US disclosed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 — — US disclosed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 — — US disclosed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20040230072-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20070078139-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B PDE4A 1/4885PDE4B 2/4885PDE4C 8/4885
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.